earnings
confidence high
sentiment positive
materiality 0.75
Iradimed reports record Q2 revenue of $20.4M (+14% YoY), raises FY2025 guidance
IRADIMED CORP
2025-Q2 EPS reported
$0.82
revenue$39,920,037
- GAAP diluted EPS of $0.45 (up 18% YoY); non-GAAP diluted EPS of $0.49 (up 17% YoY).
- Declares regular quarterly cash dividend of $0.17 per share, payable Aug 28, 2025.
- FY2025 revenue guidance raised to $80-82.5M; GAAP EPS to $1.60-1.70; non-GAAP EPS to $1.76-1.86.
- Gross profit margin held at 78%; record backlog for pump and monitor products as of June 30, 2025.
- Q3 2025 guidance: revenue $20.5-20.9M, GAAP EPS $0.41-0.45, non-GAAP EPS $0.45-0.49.